Nexpovio
What Nexpovio is used for
NEXPOVIO is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Nexpovio
- Active substance
- selinexor
- Disease area
- Multiple Myeloma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX66
- Marketing authorisation holder
- Stemline Therapeutics B.V.
- Authorised in the EU since
- 2021
Official information
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Nexpovio used for?
NEXPOVIO is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
What is the active substance in Nexpovio?
Nexpovio contains selinexor.
Who makes Nexpovio?
The EU marketing authorisation holder is Stemline Therapeutics B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU